REGENXBIO Inc. Common Stock (RGNX)
Stock · NASDAQ · Health Care
$6.93as of 10/16/2026
Price chart
Active signals
RGNX Signal Track Record
How signals performed across all stocks →What RGNX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -3.4% | 45% | September 17, 2026 |
| Bollinger Band Breakout | 23 | -5.6% | 39% | August 19, 2026 |
| Bollinger Band Breakdown | 21 | -5.4% | 43% | August 24, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -5.4% | 36% | August 5, 2026 |
| Any 20-session window (baseline) | -2.4% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabeti…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 371
- Website
- regenxbio.com/
Fundamentals
- 1-day range
- $6.88$7.18
- Market cap
- $583.15M
- P/E (trailing)
- —
- P/E (forward)
- -2.33
- EPS (trailing)
- $-3.79
- Dividend yield
- —
- Beta
- 1.21
- Avg. volume
- 1.48M
How REGENXBIO Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
REGENXBIO Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RGNXREGENXBIO Inc. Common Stock$6.93▼ 3.28%Market cap $583.15MP/E —$5.46$16.19
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RGNX REGENXBIO Inc. Common Stock | $583.15M | — | $6.93 | ▼ 3.28% | $5.46$16.19 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Microsoft upgraded, HubSpot initiated: Wall Street's top analyst callsYahoo · 10/5/2026
- Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside CallYahoo · 10/5/2026
- Full Transcript: Regenxbio Q2 2026 Earnings Callbenzinga · 10/5/2026
- Full Transcript: Regenxbio Q2 2026 Earnings CallBenzinga · 10/5/2026
- Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22Benzinga · 10/5/2026
- uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) BullishSeekingAlpha · 9/29/2026
- Regenxbio stock gains on positive gene therapy trial dataYahoo · 9/25/2026
- Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening EventsBenzinga · 9/25/2026
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific MeetingYahoo · 9/24/2026
Insider Activity
Insider Actions →- Craig Malzahn · September 1, 2026 · Tax Withholding234 @ $9.32
- Mitchell Chan · September 1, 2026 · Tax Withholding4.9K @ $9.32
- Gregory Austin Ciongoli · August 27, 2026 · Buy53.4K @ $9.36
- Gregory Austin Ciongoli · August 26, 2026 · Buy49.2K @ $9.14
- Gregory Austin Ciongoli · August 25, 2026 · Grant69.6K
- Gregory Austin Ciongoli · August 25, 2026 · Grant15.4K
- Steve Pakola · August 1, 2026 · Tax Withholding7.5K @ $9.69
- Patrick J. Christmas · August 1, 2026 · Tax Withholding4.7K @ $9.69
- Steve Pakola · July 2, 2026 · Option Exercise2.2K @ $7.86
- Steve Pakola · July 2, 2026 · Sale2.2K @ $13.64
- Steve Pakola · July 1, 2026 · Option Exercise36.7K @ $7.86
- Steve Pakola · July 1, 2026 · Sale36.7K @ $12.86
- Curran Simpson · July 1, 2026 · Tax Withholding6.8K @ $13.09
- Curran Simpson · June 30, 2026 · Grant1.5K @ $10.18
- Steve Pakola · June 29, 2026 · Sale19.6K @ $11.04
Institutional Ownership
March 31, 2026
- Total shares held
- 38.31M
- Total value held
- $316.23M
- Institutional holders
- 172
- Unknown5.78M
- Unknown4.37M
- Unknown2.73M
- Unknown2.07M
- Unknown2.01M
- Unknown1.84M
- Unknown1.50M
- Unknown1.31M
- Unknown1.14M
- Unknown1.05M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.